China’s most successful genome sequencing company, BGI Group, is set to gain a larger slice of the crucial U.S. market following a recent legal settlement with its closest American rival — amid concerns about data privacy and its links to the Chinese government.
After years of legal wrangling, the agreement inked last month between BGI’s U.S. subsidiary and San Diego-based Illumina has given the Chinese firm the green light to sell a key product, the CoolMPS sequencer, from August this
Subscribe or login to read the rest.
Subscribers get full access to:
- Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
- A weekly curated reading list on China from David Barboza, Pulitzer Prize-winning former Shanghai correspondent for The New York Times.
- A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our
Subscriptions page for details.
